Press Release: Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment

Press Release: Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment
CANNANNEW REPORT

VANCOUVER, BC, May 16, 2022 /PRNewswire/ – Numinus Wellness Inc. (“Numinus”) (TSX: NUMI) (OTC: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Health Canada has approved Numinus’ application to complete psychedelic-assisted therapy using psilocybin to treat an applicant with treatment-resistant depression. This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5th, 2022 to include access to psychedelic compounds on a case-by-case basis. Psilocybin-assisted therapy has shown a great deal of promise in treating depression, as demonstrated in recent clinical trials and studies. “I am proud that Numinus is working with Health Canada to help Canadians with mental health challenges in ways that were not previously available, including using psilocybin-assisted therapy through Health Canada’s SAP,” says Payton Nyquvest, Founder and CEO, Numinus. “The SAP recognizes a growing body of research that has consistently shown the efficacy of psychedelic-assisted psychotherapy to treat a broad range of mental health conditions that are extremely difficult to treat with conventional therapies. We hope that our first psilocybin-assisted therapy treatment is the beginning for more opportunities for Canadian patients to obtain safe access to treatment and care in the mental health sector through psychedelic medicine.” The psychedelic-assisted therapy treatment will take place at one of Numinus’ Montreal clinics, consisting of psilocybin-assisted therapy including several preparatory and integration therapy sessions, medical consults and one psilocybin-dosing session. All practitioners involved in the treatment have been trained through Numinus’ proprietary psilocybin-assisted therapy protocol and Numinus will partner with Psygen Labs, an approved Health Canada supplier, to provide the synthetic psilocybin to be taken orally during the dosing session. Dr. Andrew Bui-Nguyen, Numinus’ Québec regional medical director, who completed the application, said: “Numinus has been working…

Excerpt only …
READ MORE BELOW
Source : Press Release: Numinus Wellness Receives Health Canada Special Access Program Applicant Approval to Provide Psychedelic-assisted Therapy Treatment

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.